March 2016 Issue of The Ophthalmologist

The Power List is a celebration of excellence – and the impact it’s had on those it highlights has been impressive

Nominations for The Ophthalmologist 2016 Power List are now closed.

Benefits achieved in the first year maintained; VA performance gap in patients with low baseline vision narrows

Could transcranial direct current stimulation treat amblyopia in adults?

OpenPrescribing.net shows some interesting trends in ophthalmic therapy prescription and spend over the last five years

Racial background modifies risk; diabetes protects, but asthma and sleep apnea predisposes

Could patient self-testing help to free up eye clinics, and spot macular degeneration earlier than traditional testing methods?

Many patients visit the emergency room with ocular problems that might be better treated elsewhere – why? And what’s the solution?

From cornea to retina, NGF’s regenerative and neuroprotective potential seems immense. What does the future hold for this versatile little neurotrophin?

Last month, Peter Barry reviewed the EUREQUO registry. This month, we get the transatlantic perspective

What does analysis of the last five years of literature on corneal optical coherence tomography tell us about the priorities of the field, and the contributors to it?

Taking an ophthalmic startup from concept to reality

Refractive surgeons know the pros and cons of LASIK better than anyone – but how many would recommend it to their family, or undergo it themselves?

Sitting Down With... Anat Loewenstein, Chair of the Department of Ophthalmology, Tel Aviv Medical Centre, Professor of Ophthalmology and Vice Dean, Tel Aviv University, Israel.